Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma
About this study
The objective of this NIS is to evaluate medical resource utilization, where data is rare in all cohorts, patient's QoL and effectiveness of zanubrutinib treatment in adult patients with WM, CLL, MZL and FL in a real-world setting.
- Condition
- Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma, Follicular Lymphoma
- Tested
- Zanubrutinib, Obinutuzumab
- Sponsor
- iOMEDICO AG
Who can join
- Age
- 18 years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 11
- Minimum age: 18 years
- Study condition: Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma, Follicular Lymphoma
- Waldenström's macroglobulinemia (all treatment lines) OR
- Chronic lymphocytic leukemia (all treatment lines) OR
- Marginal zone lymphoma (≥2 treatment line and at least one anti-CD20 antibody-based previous therapy)
- Follicular lymphoma (≥3 treatment line)
- Signed and dated informed consent form
- Treatment with zanubrutinib according to current SmPC for WM, CLL and MZL
- Treatment with zanubrutinib + obinutuzumab for FL according to current SmPC
- Treatment decision before inclusion into this non-interventional study
- Age ≥18 years.
Exclusion 2
- Contraindications according to SmPC for patients with WM, CLL, MZL or FL
- Participation in an interventional clinical trial during zanubrutinib treatment.
Where
2 sites, 2 recruiting
Universitätsklinikum Salzburg, Klinik für Innere Medizin III
Salzburg, Austria
Lübecker Onkologische Schwerpunktpraxis
Lübeck, Schleswig-Holstein, Germany
Contact
-
Daniel Kummer, Dr.
+49761152420 ariadne@iomedico.com
Potential match only. Final eligibility is determined by the study team.